Literature DB >> 25908904

The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?

T Younis1, A Groom1.   

Abstract

Year:  2015        PMID： 25908904      PMCID： PMC4399613          DOI： 10.3747/co.22.2579

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  12 in total

1.  Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada.

Authors:  S Djalalov; J Beca; E Amir; M Krahn; M E Trudeau; J S Hoch
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 2.  Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review.

Authors:  Sekwon Jang; Young Kwang Chae; Tufia Haddad; Navneet S Majhail
Journal:  Breast Cancer Res Treat       Date:  2010-03-30       Impact factor: 4.872

Review 3.  American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Authors:  Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

4.  Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.

Authors:  Khalid El Ouagari; Jon Karnon; Thomas Delea; Willena Talbot; Jane Brandman
Journal:  Breast Cancer Res Treat       Date:  2006-07-04       Impact factor: 4.872

5.  Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.

Authors:  A Rocchi; S Verma
Journal:  Support Care Cancer       Date:  2006-04-05       Impact factor: 3.603

6.  Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.

Authors:  T Younis; D Rayson; R Dewar; C Skedgel
Journal:  Ann Oncol       Date:  2006-11-09       Impact factor: 32.976

7.  Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.

Authors:  Aysegul Erman; Arlene Nugent; Eitan Amir; Peter C Coyte
Journal:  Breast Cancer Res Treat       Date:  2014-04-26       Impact factor: 4.872

8.  Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.

Authors:  Thomas E Delea; Khalid El-Ouagari; Jonathan Karnon; Oleg Sofrygin
Journal:  Breast Cancer Res Treat       Date:  2007-07-26       Impact factor: 4.872

9.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Authors:  Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

Review 10.  A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer.

Authors:  Ava A John-Baptiste; Wei Wu; Paula Rochon; Geoffrey M Anderson; Chaim M Bell
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.